Cargando…
Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
Autores principales: | Laribi, Kamel, Baugier de Materre, Alix, Touileb, Yamina, Boursot, Charles, Sandrini, Jeremy, Cavalieri, Doriane, Pastoret, Cédric, de Leval, Laurence, Tournilhac, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812600/ https://www.ncbi.nlm.nih.gov/pubmed/35141469 http://dx.doi.org/10.1097/HS9.0000000000000675 |
Ejemplares similares
-
Advances in the understanding and management of T-cell prolymphocytic leukemia
por: Laribi, Kamel, et al.
Publicado: (2017) -
Quadri‐lineage disease involving nodal B‐cell marginal zone lymphoma, high‐grade B‐cell lymphoma, Kaposi's syndrome, and acute myeloid leukemia
por: Laribi, Kamel, et al.
Publicado: (2015) -
Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine
por: Laribi, Kamel, et al.
Publicado: (2019) -
Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: Wang, Wei, et al.
Publicado: (2022) -
Retracted: Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)